Market Research Industry Reports

Market Access Impact (EU5) [NSCLC]

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS

Eliminating prescription barriers could break the tie at the top of the market

The two leading brands in the EU5 non-small cell lung cancer (NSCLC) market are tied for market share, but one of them benefits more from market barriers that prevent oncologists from prescribing competing treatments. Eliminating those barriers could help the other leading brand take a narrow, but significant lead.

Get the details in Market Access Impact: NSCLC (EU5).

You’ll see how widely prescribed your brand is, and learn how 7 barriers affect your market share. You’ll also find out how much share you win and lose, who you take share from, and who gets your lost share.

Based on a survey of 150 medical oncologists from the EU5 countries (France, Germany, Italy Spain, UK), the report covers 10 major therapies from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck Sharpe & Dohme, Novartis, Pfizer/Merck Group, and Roche.

Not your market? Click here to see the US report


Top Takeaways

Market access is a key concern: While barriers affect over 15% of prescriptions overall, market access barriers are responsible for nearly a third of that impact.
More brands lose out: Barriers cause more brands to lose market share than to gain, and the losses tend to be bigger than gains.
Tie-breaker: The two leading brands have equal market share, but eliminating barriers would cause one of them to lose enough share to give the other a narrow lead.
Problem areas: Some barriers have an outsized effect on some brands, e.g., reimbursement and formulary availability are the issues for the brand in the last-place.
Barrier effect is widespread: 45–65% of doctors experience at least one or more barriers with every surveyed brand.
Overall perception is good: Most doctors either prescribe, or would consider prescribing all of the surveyed brands, and no more than 5% of doctors are unaware of any given brand.

Insight into 10 Major NSCLC Drugs

Avastin (bevacizumab; Roche)
Cyramza (ramucirumab; Eli Lilly)
Giotrif (afatinib; Boehringer Ingelheim)
Iressa (gefitinib; AstraZeneca)
Keytruda (pembrolizumab; Merck Sharpe & Dohme)
Opdivo (nivolumab; Bristol-Myers Squibb)
Tagrisso (osimertinib; AstraZeneca)
Tarceva (erlotinib; Roche)
Xalkori (crizotinib; Pfizer/Merck Group)
Zykadia (ceritinib; Novartis)

Exploring Market Access Barriers

Market Access Impact: NSCLC (EU5) explores key issues affecting drug manufacturers. You’ll learn:

How barriers affect market access:

What brands do doctors prescribe the most?
How many prescriptions do barriers affect?
Which barriers have the biggest impact?

How barriers affect your brand:

How many doctors prescribe your brand? How many don’t, but would consider it?
Why don’t doctors prescribe your brand? What do they prescribe instead?
Which competing brands does your brand take market share from?


A Report Based on Expert Knowledge

We surveyed 150 medical oncologists—30 from each EU5 country (France, Italy, Germany, Spain, UK)—chosen from the largest community of validated physicians in the world.

All respondents:

Have been practicing for 2+ years
Prescribed at least one of the listed products
Seen at least 5 patients with NSCLC in total in the last month

1. What are market barriers?
2. About this report
3. About the survey
4. Brands included in the survey
5. Executive summary


Calcium Chloride Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023

Calcium chloride, chemically known as CaCl2, is an inorganic salt which is highly soluble in water. It stays as a colourless crystalline solid at room temperature, however it is deliquescent

USD 1799View Report

Salmon Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023

Salmon belong to the family Salmonidae and are found in the northern Atlantic and Pacific oceans. They are anadromous, this means that most types of salmon are born in fresh

USD 1499View Report

Market Access Impact: Type 2 Diabetes Mellitus [Orals] (US) 2018

Market barriers only affect over a third of oral diabetes treatment prescriptions in the US. Is your brand losing outMarket barriers affect over a third of all oral type 2

USD 5345View Report

Market Access Impact: Type 2 Diabetes Mellitus [Orals] (EU5) 2018

Market barriers affect a fifth of oral diabetes treatment prescriptions in Europe. Is your brand losing outMarket barriers affect over a fifth of all oral type 2 diabetes mellitus (T2DM)

USD 5345View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 5145
  • Enterprise Wide Licence    USD 7725
$ 5145

Reports Details

Published Date : Aug 2017
Country :Global
Category :Healthcare
Publisher :FirstWord Dossier
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube